New Drug Approvals

NKTR 214 February 15, 2018 - (0)

CAS 946414-94-4 BMS 936558 MDX 1106 NKTR 214 ONO 4538 Opdivio NIVOLUMAB Pegylated engineered interleukin-2 (IL-2) with altered receptor binding NKTR-214 is a cytokine (investigational agent) that is designed to target CD122, a protein which is found on certain immune cells (known as CD8+ T Cells and Natural Killer Cells) to expand these cells to promote […]
FDA approves new treatment Erleada (apalutamide) for a certain type of prostate cancer using novel clinical trial endpoint February 15, 2018 - (0)
Abaloparatide, абалопаратид , أبالوباراتيد , 巴罗旁肽 , February 13, 2018 - (1)
Pfizer’s Monobactam PF-? February 12, 2018 - (0)
Design, synthesis and biological evaluation of novel 5-hydroxy-2-methyl-4H-pyran-4-one derivatives as antiglioma agents February 8, 2018 - (1)

Mobile Site | Full Site